PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Blue Cross & Blue Shield of MississippiAll Plans · Coverage · Medical Policy · Urology, OB-GYN, GastroenterologyMedium impact

Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

Effective date
Not stated in the notice
Identified
Jun 20, 2026

Summary

Carbon-coated spheres, calcium hydroxylapatite, polyacrylamide hydrogel, or polydimethylsiloxane may be considered medically necessary to treat stress urinary incontinence in men and women who have failed appropriate conservative therapy. Autologous cellular therapy, autologous fat, autologous ear chondrocytes, and any other periurethral bulking agent, including Teflon, are investigational for stress urinary incontinence. Periurethral bulking agents for urge urinary incontinence and perianal bulking agents for fecal incontinence are also investigational.

Get alerts when payers change rules like this one

We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.

Get Blue Cross & Blue Shield of Mississippi alertsPolicy Monitoring is free. No card required.

What to do

Action · 3 steps
01Claims for periurethral bulking agents for stress urinary incontinence need documentation of an inadequate response to conservative therapy, which in general should have been used for at least 3 months.
02Conservative therapy includes pelvic floor muscle exercises and behavioral changes such as fluid management and moderation of physical activities that provoke incontinence, and additional options include intravaginal estrogen therapy, use of a pessary, and treatment of other underlying causes.
03Claims for Federal Employee Program members may be assessed only on the basis of medical necessity for FDA-approved devices, because the program may not consider them investigational.

Codes mentioned

51715L8603L8606Q3031N36.41N36.43N36.42N36.8N39.3R32N39.46N39.42N39.43N39.44N39.45N39.498R39.8146999L8605

Original notice

Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
bcbsms.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account